Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis.

Marty FM, Yeh WW, Wennersten CB, Venkataraman L, Albano E, Alyea EP, Gold HS, Baden LR, Pillai SK.

J Clin Microbiol. 2006 Feb;44(2):595-7.

2.

In vitro activity of an oral streptogramin antimicrobial, XRP2868, against gram-positive bacteria.

Eliopoulos GM, Ferraro MJ, Wennersten CB, Moellering RC Jr.

Antimicrob Agents Chemother. 2005 Jul;49(7):3034-9.

3.

In vitro activity of the new oxazolidinone AZD2563 against Enterococci.

Eliopoulos GM, Wennersten CB, Moellering RC Jr.

Antimicrob Agents Chemother. 2002 Oct;46(10):3273-5.

4.
5.

In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria.

Boucher HW, Wennersten CB, Eliopoulos GM.

Antimicrob Agents Chemother. 2000 Aug;44(8):2225-9.

6.

Activities of taurolidine in vitro and in experimental enterococcal endocarditis.

Torres-Viera C, Thauvin-Eliopoulos C, Souli M, DeGirolami P, Farris MG, Wennersten CB, Sofia RD, Eliopoulos GM.

Antimicrob Agents Chemother. 2000 Jun;44(6):1720-4.

7.

In-vitro activity of the new ketolide antibiotic HMR 3647 against gram-positive bacteria.

Schülin T, Wennersten CB, Moellering RC Jr, Eliopoulos GM.

J Antimicrob Chemother. 1998 Sep;42(3):297-301.

PMID:
9786468
8.

Susceptibilities of Legionella spp. to newer antimicrobials in vitro.

Schülin T, Wennersten CB, Ferraro MJ, Moellering RC Jr, Eliopoulos GM.

Antimicrob Agents Chemother. 1998 Jun;42(6):1520-3.

9.

In vitro activity of BAY 12-8039, a new fluoroquinolone, against species representative of respiratory tract pathogens.

Souli M, Wennersten CB, Eliopoulos GM.

Int J Antimicrob Agents. 1998 Apr;10(1):23-30.

PMID:
9624540
10.

Characterization of vancomycin-resistant Enterococcus faecium isolates from the United States and their susceptibility in vitro to dalfopristin-quinupristin.

Eliopoulos GM, Wennersten CB, Gold HS, Schülin T, Souli M, Farris MG, Cerwinka S, Nadler HL, Dowzicky M, Talbot GH, Moellering RC Jr.

Antimicrob Agents Chemother. 1998 May;42(5):1088-92.

11.
13.

In vitro activity of RU 64004, a new ketolide antibiotic, against gram-positive bacteria.

Schülin T, Wennersten CB, Moellering RC Jr, Eliopoulos GM.

Antimicrob Agents Chemother. 1997 May;41(5):1196-202.

14.

In vitro activities in new oxazolidinone antimicrobial agents against enterococci.

Eliopoulos GM, Wennersten CB, Gold HS, Moellering RC Jr.

Antimicrob Agents Chemother. 1996 Jul;40(7):1745-7.

15.

Comparative in vitro activity of levofloxacin and ofloxacin against gram-positive bacteria.

Eliopoulos GM, Wennersten CB, Moellering RC Jr.

Diagn Microbiol Infect Dis. 1996 May;25(1):35-41.

PMID:
8831043
16.

In vitro activity of WY-49605, a penem antimicrobial.

Eliopoulos GM, Wennersten CB, Cole G, Moellering RC Jr.

Int J Antimicrob Agents. 1995 Jul;5(4):251-7.

PMID:
18611676
17.

In vitro activity of A-86719.1, a novel 2-pyridone antimicrobial agent.

Eliopoulos GM, Wennersten CB, Cole G, Chu D, Pizzuti D, Moellering RC Jr.

Antimicrob Agents Chemother. 1995 Apr;39(4):850-3.

18.

In vitro activities of two glycylcyclines against gram-positive bacteria.

Eliopoulos GM, Wennersten CB, Cole G, Moellering RC.

Antimicrob Agents Chemother. 1994 Mar;38(3):534-41.

19.

Comparative activities of piperacillin and tazobactam against clinical isolates of Legionella spp.

Collins LA, Wennersten CB, Ferraro MJ, Moellering RC Jr, Eliopoulos GM.

Antimicrob Agents Chemother. 1994 Jan;38(1):144-6.

20.

A gene conferring resistance to vancomycin but not teicoplanin in isolates of Enterococcus faecalis and Enterococcus faecium demonstrates homology with vanB, vanA, and vanC genes of enterococci.

Gold HS, Unal S, Cercenado E, Thauvin-Eliopoulos C, Eliopoulos GM, Wennersten CB, Moellering RC Jr.

Antimicrob Agents Chemother. 1993 Aug;37(8):1604-9.

21.

In vitro activity of ramoplanin against vancomycin-resistant gram-positive organisms.

Collins LA, Eliopoulos GM, Wennersten CB, Ferraro MJ, Moellering RC Jr.

Antimicrob Agents Chemother. 1993 Jun;37(6):1364-6.

22.

In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms.

Collins LA, Malanoski GJ, Eliopoulos GM, Wennersten CB, Ferraro MJ, Moellering RC Jr.

Antimicrob Agents Chemother. 1993 Mar;37(3):598-601.

23.

Influence of high-level gentamicin resistance and beta-hemolysis on susceptibility of enterococci to the bactericidal activities of ampicillin and vancomycin.

Cercenado E, Eliopoulos GM, Wennersten CB, Moellering RC Jr.

Antimicrob Agents Chemother. 1992 Nov;36(11):2526-8.

24.

Absence of synergistic activity between ampicillin and vancomycin against highly vancomycin-resistant enterococci.

Cercenado E, Eliopoulos GM, Wennersten CB, Moellering RC Jr.

Antimicrob Agents Chemother. 1992 Oct;36(10):2201-3.

25.

Increasing resistance to beta-lactam antibiotics among clinical isolates of Enterococcus faecium: a 22-year review at one institution.

Grayson ML, Eliopoulos GM, Wennersten CB, Ruoff KL, De Girolami PC, Ferraro MJ, Moellering RC Jr.

Antimicrob Agents Chemother. 1991 Nov;35(11):2180-4.

26.

Comparison of Enterococcus raffinosus with Enterococcus avium on the basis of penicillin susceptibility, penicillin-binding protein analysis, and high-level aminoglycoside resistance.

Grayson ML, Eliopoulos GM, Wennersten CB, Ruoff KL, Klimm K, Sapico FL, Bayer AS, Moellering RC Jr.

Antimicrob Agents Chemother. 1991 Jul;35(7):1408-12.

27.

Multiply high-level-aminoglycoside-resistant enterococci isolated from patients in a university hospital.

Nachamkin I, Axelrod P, Talbot GH, Fischer SH, Wennersten CB, Moellering RC Jr, MacGregor RR.

J Clin Microbiol. 1988 Jul;26(7):1287-91.

28.

A novel mechanism of resistance to penicillin-gentamicin synergism in Streptococcus faecalis.

Moellering RC Jr, Murray BE, Schoenbaum SC, Adler J, Wennersten CB.

J Infect Dis. 1980 Jan;141(1):81-6.

PMID:
6767791
29.

Species-specific resistance to antimocrobial synergism in Streptococcus faecium and Streptococcus faecalis.

Moellering RC Jr, Korzeniowski OM, Sande MA, Wennersten CB.

J Infect Dis. 1979 Aug;140(2):203-8.

PMID:
113469

Supplemental Content

Loading ...
Support Center